🔥🐔 BizChicken 🐔🔥
Companies Similar to UroGen Pharma Ltd.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Biogen Inc.
TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS
Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.
About | About | Vision/Values | Leadership | Foundation | Contact | Careers | Careers | Careers | Careers | Careers | About | About | Careers | Careers | Careers | Careers | Benefits | Careers | Careers | Careers | Careers | About | About | About | About
Symbol: BIIB
Recent Price: $150.19
Industry: Drug Manufacturers - General
CEO: Mr. Christopher A. Viehbacher
Sector: Healthcare
Employees: 7570
Address: 225 Binney Street, Cambridge, MA 02142
Phone: 617 679 2000
Leadership
- Christopher A. Viehbacher, President and Chief Executive Officer
- Susan H. Alexander, Chief Legal Officer
- Ginger Gregory, Ph.D., Chief Human Resources Officer
- Jane Grogan, Ph.D., Head of Research
- Rachid Izzar, Head of Global Product Strategy & Commercialization
- Adam Keeney, Head of Corporate Development
- Michael McDonnell, Chief Financial Officer
- Nicole Murphy, Head of Pharmaceutical Operations and Technology
- Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
- Alisha Alaimo, President, Head of North America
- Stephen Amato, Head of Investor Relations
- Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
- Fraser Hall, President, Head of Intercontinental Region
- Wolfram Schmidt, President, Head of Europe
- Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
- Caroline Dorsa, Chair of the Board
- Maria C. Freire, Ph.D., Director
- William A. Hawkins, Director
- Susan Langer, Director
- Jesus B. Mantas, Director
- Lloyd B. Minor, M.D., Director
- Monish Patolawala, Director
- Eric K. Rowinsky, M.D., Director
- Stephen A. Sherwin, M.D., Director
Last updated: 2024-12-31
Elicio Therapeutics, Inc.
ELI-002
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.
Symbol: ELTX
Recent Price: $5.00
Industry: Biotechnology
CEO: Mr. Robert T. Connelly
Sector: Healthcare
Employees: 32
Address: 451 D Street, Boston, MA 02210
Phone: 857-209-0050
Last updated: 2024-12-31
PharmaCyte Biotech, Inc.
Cell-in-a-Box
Pharma Cyte Biotech, Inc. is a biotechnology company focused on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites. Their therapies are based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology, used for treating various cancers and diabetes.
About | Management | Directors | ESG | About | Directors | Contact | ESG | About | About | About | About
Symbol: PMCB
Recent Price: $1.55
Industry: Biotechnology
CEO: Mr. Joshua N. Silverman
Sector: Healthcare
Employees: 2
Address: 3960 Howard Hughes Parkway, Las Vegas, NV 89169
Phone: 917 595 2850
Leadership
- Joshua N. Silverman, Independent Director
- Dr. Michael M. Abecassis, Independent Director
- Robert Weinstein, Director
- Wayne R. Walker, Director
- Jonathan L. Schechter, Independent Director
- Dr. Abecassis, Director
- Kenneth L. Waggoner, Independent Director
- Daniel C. Farb, Independent Director
- Daniel C. Allen, Independent Director
- Jack E. Stover, Independent Director
Last updated: 2024-12-31
Tyra Biosciences, Inc.
TYRA-300
Tyra Biosciences, Inc. is a preclinical-stage biopharmaceutical company focused on developing therapies to overcome tumor resistance and enhance outcomes for cancer patients. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 for treating muscle invasive bladder cancer.
Symbol: TYRA
Recent Price: $13.90
Industry: Biotechnology
CEO: Dr. Todd Harris Ph.D.
Sector: Healthcare
Employees: 49
Address: 2656 State Street, Carlsbad, CA 92008
Phone: 619 728 4760
Last updated: 2024-12-31
Agenus Inc.
Retrocyte Display
Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.
Symbol: AGEN
Recent Price: $2.69
Industry: Biotechnology
CEO: Dr. Garo H. Armen Ph.D.
Sector: Healthcare
Employees: 389
Address: 3 Forbes Road, Lexington, MA 02421-7305
Phone: 781 674 4400
Last updated: 2024-12-31
BeiGene, Ltd.
BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy
Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.
About | About | Vision/Values | About | About | Culture | DEI | Culture | Leadership | About | Contact | Careers | Careers | Careers | Careers | About | About | About | About | About | Jobs | About | About | About
Symbol: BGNE
Recent Price: $183.81
Industry: Biotechnology
CEO: Mr. John V. Oyler
Sector: Healthcare
Employees: 10000
Address: 55 Cambridge Parkway, Cambridge, MA 02142
Phone: 781-801-1800
Leadership
- John V. Oyler, Co-Founder, Chairman and CEO
- Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
- Olivier Brandicourt, M.D., Director
- Margaret Dugan, M.D., Director
- Donald W. Glazer, Director
- Michael Goller, Director
- Anthony Hooper, Director
- Ranjeev Krishana, Director
- Michael Nuoqing Yi, Director
- Alessandro Riva, M.D., Director
- Corsee Sanders, Ph.D., Director
- Shalini Sharp, Director
- Steven Young, Ph.D., Acting Head of Medicinal Chemistry
- Ron Levy, M.D., Scientific Advisory Board
- Neal Rosen, M.D., Ph.D., Scientific Advisory Board
- Charles Sawyers, M.D., Scientific Advisory Board
- David Schenkein, M.D., Scientific Advisory Board
- Melika Davis, SVP & Global Head, Clinical Operations
- Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
- Tony Guo, Ph.D., SVP, Global Statistics & Data Science
- Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
- Graham Hardiman, Global Head of HR
- Shreya Devendra Jani, SVP, Corporate Affairs
- Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
- Yang Ji, Chief Compliance Officer
- Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
- Chan Lee, General Counsel
- Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
- Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
- Kyoung Lim, VP of Supply Chain
- Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
- Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
- Richard O’Keeffe, Head of Global Quality
- Jurij Petrin, M.D., Head of New Market Development
- Yan Qi, Ph.D., SVP, Head of Public Affairs
- Hongyu Qian, SVP, Medical Affairs
- Jason Radford, SVP, Strategy & Corporate Development
- Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
- Adam Roach, VP and Head of Asia Pacific
- Aaron Rosenberg, Chief Financial Officer
- Michael Schoen, Strategic Advisor and Special Assistant to the CEO
- Matt Shaulis, General Manager of North America
- Lai Wang, Ph.D., Global Head of R&D
- Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
- Beth Wensley, SVP, Head of Portfolio and Program Management
- Kimberly Wolf, SVP, Global Commercial Strategy & Operations
- Xiaobin Wu, Ph.D., President, Chief Operating Officer
- Eva Yin, Chief Commercial Officer, Greater China
Last updated: 2024-12-31
Celularity Inc.
CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.
About | Leadership | Directors | About | About | About | About | Directors | Careers | About | About | About | About | About | About
Symbol: CELU
Recent Price: $2.05
Industry: Biotechnology
CEO: Dr. Robert Joseph Hariri M.D., Ph.D.
Sector: Healthcare
Employees: 120
Address: 170 Park Avenue, Florham Park, NJ 07932
Phone: 908 768 2170
Leadership
- Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
- David Beers, CFA, Chief Financial Officer
- Stephen Brigido, DPM, President, Degenerative Diseases
- John Haines, Global Manager and Chief Administrative Officer
- K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
- John Colerangle, DVM, Ph.D., Regulatory Affairs
- Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
- Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
- Carmine Palummo, Corporate Operations
- Tim Wilk, Technical Operations
- Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
- Peter Diamandis, M.D., Director
- Dean Kehler, Director
- Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
- Diane Parks, Director
Last updated: 2024-12-31
Cogent Biosciences, Inc.
CGT9486
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.
Symbol: COGT
Recent Price: $7.67
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Employees: 164
Address: 200 Cambridge Park Drive, Cambridge, MA 02140
Phone: 617 945 5576
Last updated: 2024-12-31
GlycoMimetics, Inc.
uproleselan
Glyco Mimetics, Inc. is a clinical-stage biotechnology company that focuses on discovering and developing novel glycomimetic drugs to address unmet medical needs related to diseases, currently developing treatments for conditions such as acute myeloid leukemia and cancers affecting bone and bone marrow.
Symbol: GLYC
Recent Price: $0.25
Industry: Biotechnology
CEO: Mr. Harout Semerjian
Sector: Healthcare
Employees: 35
Address: 9708 Medical Center Drive, Rockville, MD 20850
Phone: 240 243 1201
Last updated: 2024-12-31
Incyte Corporation
JAKAFI, PEMAZYRE, ICLUSIG
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.
About | Leadership | Contact | Contact | Locations | Contact | Contact | Culture | Jobs | Culture | DEI | News | Events | About | About | Careers | Jobs | Careers | Careers | DEI | Culture | Careers | Culture | DEI | Careers | Locations | Careers | About | About | About | About | About | Careers | About | About | Culture
Symbol: INCY
Recent Price: $68.42
Industry: Biotechnology
CEO: Mr. Herve Hoppenot
Sector: Healthcare
Employees: 2524
Address: 1801 Augustine Cut-Off, Wilmington, DE 19803
Phone: 302 498 6700
Leadership
- Hervé Hoppenot, Chairman and Chief Executive Officer
- Paula J. Swain, Executive Vice President, Human Resources
- Pablo J. Cagnoni, M.D., President, Head of Research and Development
- Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
- Sheila A. Denton, J.D., Executive Vice President and General Counsel
- Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
- Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
- Denise Brashear, Vice President, Head of Global Communications
- Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
- Lee Heeson, Executive Vice President, Head of Incyte International
- Michael Morrissey, Executive Vice President and Head of Global Technical Operations
- Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
- Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
- Julian C. Baker, Managing Partner
- Jean-Jacques Bienaime, Former Chief Executive Officer
- Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
- Paul J. Clancy, Former Executive Vice President and Senior Advisor
- Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
- Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
- Katherine High, M.D., Former President and Head of Research and Development
- Susanne Schaffert, Ph.D., Former President
Last updated: 2024-12-31
Kymera Therapeutics, Inc.
novel small molecule therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
About | About | Leadership | Foundation | Contact | Culture | About | About | Leadership | Foundation | About | About | About | Culture | Culture | Culture | Culture | About | About
Symbol: KYMR
Recent Price: $39.32
Industry: Biotechnology
CEO: Dr. Nello Mainolfi M.D., Ph.D.
Sector: Healthcare
Employees: 184
Address: 200 Arsenal Yards Boulevard, Watertown, MA 02472
Phone: 857 285 5300
Leadership
- Nello Mainolfi, Ph.D., Founder, President & CEO
- Jeremy Chadwick, Ph.D., Chief Operating Officer
- Ellen Chiniara, JD, Chief Legal Officer and Corporate Secretary
- Jared Gollob, MD, Chief Medical Officer
- Bruce Jacobs, CFA, MBA, Chief Financial Officer
- Karen Weisbach, Head of People and Culture
- Juliet Williams, Ph.D., Head of Research
- Bruce Booth, DPhil, Chairman and Co-Founder
- Felix J. Baker, PhD, Lead Independent Director
- Jeff Albers, JD, MBA,
- Pamela Esposito, PhD,
- Gorjan Hrustanovic, PhD,
- John Maraganore, PhD,
- Leigh Morgan,
- Victor Sandor, MDCM,
- Elena Ridloff, CFA,
Last updated: 2024-12-31
Ultragenyx Pharmaceutical Inc.
Crysvita, Mepsevii, Dojolvi, Evkeeza, DTX401, DTX301
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare and ultra-rare genetic diseases worldwide.
Leadership | About | About | About
Symbol: RARE
Recent Price: $42.27
Industry: Biotechnology
CEO: Dr. Emil D. Kakkis M.D., Ph.D.
Sector: Healthcare
Employees: 1276
Address: 60 Leveroni Court, Novato, CA 94949
Phone: 415 483 8800
Last updated: 2024-12-31
Rocket Pharmaceuticals, Inc.
Gene Therapies
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.
Symbol: RCKT
Recent Price: $12.03
Industry: Biotechnology
CEO: Dr. Gaurav D. Shah M.D.
Sector: Healthcare
Employees: 268
Address: 9 Cedarbrook Drive, Cranbury, NJ 08512
Phone: 609 659 8001
Last updated: 2024-12-31
Regulus Therapeutics Inc.
RG-012 and RGLS8429
Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.
Symbol: RGLS
Recent Price: $1.50
Industry: Biotechnology
CEO: Mr. Joseph P. Hagan M.B.A.
Sector: Healthcare
Employees: 30
Address: 4224 Campus Point Court, San Diego, CA 92121
Phone: 858 202 6300
Last updated: 2024-12-31
Rallybio Corporation
RLYB212
Rallybio Corporation is a clinical-stage biotechnology company focused on discovering, developing, manufacturing, and delivering therapies for severe and rare diseases, with a lead product candidate RLYB212 in clinical trials.
Contact | About | About | About | About | Careers | Careers | Careers | Careers | Careers | Careers | About | About
Symbol: RLYB
Recent Price: $0.93
Industry: Biotechnology
CEO: Dr. Stephen Uden M.B, M.D.
Sector: Healthcare
Employees: 25
Address: 234 Church Street, New Haven, CT 06510
Phone: 203 859 3820
Last updated: 2024-12-31
Soligenix, Inc.
SGX301 (Hy Bryte), SGX942, SGX203, SGX302
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, operating in the Specialized Bio Therapeutics and Public Health Solutions segments.
About | Directors | About | About | About | About | About | About | Contact | About | About | About | About | About | Careers | Careers | About | About | About | About | About | About | About
Symbol: SNGX
Recent Price: $2.91
Industry: Biotechnology
CEO: Dr. Christopher J. Schaber Ph.D.
Sector: Healthcare
Employees: 13
Address: 29 Emmons Drive, Princeton, NJ 08540
Phone: 609 538 8200
Leadership
- Christopher J. Schaber, PhD, Chairman, President and Chief Executive Officer
- Gregg A. Lapointe, CPA, MBA, Board Director
- Diane L. Parks, MBA, Board Director
- Robert J. Rubin, MD, Board Director
- Jerome Zeldis, MD, PhD, Board Director
Last updated: 2024-12-31
Syros Pharmaceuticals, Inc.
Tamibarotene
Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control medicines. Key products include Tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, and SY-5609 for advanced solid tumors.
About | Leadership | Directors | About | Contact | Careers | Vision/Values | DEI | Careers | About | About
Symbol: SYRS
Recent Price: $0.25
Industry: Biotechnology
CEO: Mr. Conley Chee
Sector: Healthcare
Employees: 68
Address: 35 CambridgePark Drive, Cambridge, MA 02140
Phone: 617 744 1340
Leadership
- Conley Chee, President and Chief Executive Officer
- Jason Haas, Chief Financial Officer
- Gerald E. Quirk, Chief Legal & Compliance Officer; Chief Business Officer
- Lisa Roberts, VP Human Resources
- David A. Roth, M.D., Chief Medical Officer
- Kristin Stephens, Chief Development Officer
Last updated: 2024-12-31
TG Therapeutics, Inc.
Ublituximab, Umbralisib, Cosibelimab, TG-1701, TG-1801
TG Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.
About | About | Leadership | About | About | About | About | Our Story | Contact | Contact | About | About
Symbol: TGTX
Recent Price: $31.45
Industry: Biotechnology
CEO: Mr. Michael S. Weiss Esq.
Sector: Healthcare
Employees: 264
Address: 2 Gansevoort Street, New York, NY 10014
Phone: 212 554 4484
Leadership
- Michael S. Weiss, Chairman, President, and Chief Executive Officer
- Sean A. Power, CPA, Chief Financial Officer
- Adam Waldman, Chief Commercialization Officer
Last updated: 2024-12-31
UroGen Pharma Ltd.
RTGel and Jelmyto
Uro Gen Pharma Ltd. develops and commercializes novel solutions for specialty cancers and urothelial diseases, with products like RTGel and Jelmyto and a focus on non-muscle invasive urothelial cancer treatments.
Symbol: URGN
Recent Price: $10.52
Industry: Biotechnology
CEO: Ms. Elizabeth A. Barrett
Sector: Healthcare
Employees: 203
Address: 400 Alexander Park, Princeton, NJ 08540
Phone: 646 768 9780
Last updated: 2024-12-31
Tango Therapeutics, Inc.
TNG908
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.
Symbol: TNGX
Recent Price: $3.10
Industry: Biotechnology
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Employees: 140
Address: 100 Binney Street, Cambridge, MA 02142
Phone: 857 320 4900
Last updated: 2024-12-31